17 results
6-K
EX-99.1
KMDA
Kamada Ltd
6 Feb 19
Kamada Announces Additional Interim Results from Phase 2 Proof
7:00am
were accepted for presentation at the International Society for Heart and Lung Transplantation 2019 Annual Meeting and Scientific Sessions, which … to 72 hours after lung transplantation. PGD develops in approximately 20-30% of all lung transplant recipients. According to the International Society
6-K
EX-99.1
fm092y9rpq
6 Apr 16
Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1
12:00am
6-K
EX-99.1
1r2oume2cy16be2 lad
20 Apr 15
Kamada Reports Additional Data from European Phase 2/3 Clinical Study of
12:00am
6-K
EX-99.1
cm86em1 ri1yqrx
23 Mar 15
Kamada Awarded European Orphan Drug Designation for its Alpha-1 Antitrypsin
12:00am
6-K
EX-99.1
zbcyc6jcltua
2 Feb 15
Current report (foreign)
12:00am
6-K
EX-99.1
jvv64mpz30
7 Jan 15
Kamada Reports Encouraging Discussions with European Co-Rapporteurs
12:00am
6-K
EX-99.1
9xs359
11 Dec 14
Kamada Announces Positive Interim Results from Phase I/II Clinical Study of its
12:00am
6-K
t8y9qxf0bjti 8k2
11 Dec 14
Kamada Announces Positive Interim Results from Phase I/II Clinical Study of its
12:00am
6-K
EX-99.1
vthb n67204jff2pezql
21 Mar 14
Kamada to Report Top-Line Data from Phase 2/3 Clinical Trial of Inhaled AAT to
12:00am
6-K
EX-99.1
pyrq240kn9o281 dv
31 Oct 13
Current report (foreign)
12:00am
- Prev
- 1
- Next